drugset

drugset / Trial / NCT00057395

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

NCT00057395 ↗

Phase 1/2 Unknown 40 enrolled Aronex Pharmaceuticals

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aroplatin	Small molecule	—	—

Indications